% | $
Quotes you view appear here for quick access.

Affymax, Inc. Message Board

  • fternoss fternoss Feb 26, 2013 4:24 PM Flag

    Subcutaneous (SQ) Administration of Omontys is safe and effective

    There is no good clinical reason to administer Omontys intravenously. All Affymax has to do is reintroduce it for subcutaneous (SQ) administration only. According to the recall news, there were no hypersensitivity reactions or deaths reported with subcutaneous administration. IN addition, Amgen's ESAs (Epogen & Aranesp) have the same hypersensitivity warnings as Affymax's Omontys. Actually the SQ adminstration is better and probably more effective for dialysis patients. I invested heavily in the stock today because my expertise as a pharmacist tells me that elimination of the intravenous administration will not have any significant adverse impact on the use and future growth of the drug. In my opinion Omontys is a major advance in the ESA therapy and once a motnh SQ administration presents many advantages over the three times a week Epogen administration.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.061-0.0088(-12.54%)Aug 26 10:53 AMEDT